Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection.
OBJECTIVE
To evaluate the effects of treatment with the gonadotropin releasing hormone (GnRH) agonist goserelin before endometrial resection on absorption of distension medium fluid and technical feasibility of the surgical procedure.


METHODS
Fifty-five patients reporting menorrhagia underwent endometrial resection after 2 months of goserelin depot therapy (33 cases) or during the proliferative phase of the cycle (22 controls).


RESULTS
In the cases, the mean distension medium deficit +/- S.D. was 511 +/- 196 ml versus 647 +/- 245 ml in controls (P = 0.03), and the operating times were, respectively, 14 +/- 4 versus 18 +/- 5 min (P = 0.002). The intrauterine operating conditions were considered excellent or good in 64% of the cases versus 27% of the controls (chi 2 = 5.60, P = 0.02).


CONCLUSIONS
GnRH agonists induce endometrial thinning, so that when administered before intrauterine interventions, mucus cellular debris and bleeding should be reduced during surgery and hysteroscopic visibility increased; the operating time may thus be shorter and fluid absorption decreased. However, more data are needed before considering GnRH agonists a proven effective means of facilitating endometrial resection.
Vercellini
P
P
Clinica Ostetrica e Ginecologica L. Mangiagalli, dell'Università di Milano, Italy.
Trespidi
L
L
Bramante
T
T
Panazza
S
S
Mauro
F
F
Crosignani
P G
PG
D000328:Adult; D004717:Endometrium / Q000601:surgery*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D015907:Hysteroscopy; D008595:Menorrhagia / Q000601:surgery*; D008875:Middle Aged; D011300:Preoperative Care
D017273:Goserelin